Geneos Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Geneos Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-242	Closed	-$736	–	3183
2024 Q4	$736	Hold	242	–	–	﹤0.01%	2832
2024 Q3	$1.26K	Buy	+242	New	+$1.2K	﹤0.01%	2396
2021 Q4	–	Sell	-5,840	Closed	-$162K	–	2895
2021 Q3	$162K	Hold	5,840	–	–	0.01%	952
2021 Q2	$177K	Sell	5,840 -200	-3%	-$5.77K	0.01%	903
2021 Q1	$175K	Hold	6,040	–	–	﹤0.01%	1031
2020 Q4	$163K	Buy	+6,040	New	+$156K	0.01%	914

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Geneos Wealth Management's RVNC Position: Q1 2025 in Review

Geneos Wealth Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 242 shares — an estimated $736 sold.

Geneos Wealth Management first reported a position in RVNC in Q4 2020 and held it in 6 quarters. The position peaked at $177K in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Geneos Wealth Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Geneos Wealth Management sold 242 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $736.
Geneos Wealth Management first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 6 quarters.
Geneos Wealth Management's Revance Therapeutics, Inc. position peaked at $177K in Q2 2021.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Geneos Wealth Management's 13F filing for Q1 2025, filed 8 May 2025.